PG-530742

DB05495InvestigationalSmall molecule

PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression.... Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

Mechanism: PG-530742 selectively inhibits certain matrix metalloproteinases: In an independent research study, the drug-treated group showed decreased levels of MMP-2, -3, -9, and -13.
Curator reviewed
Primary indication: Investigated for use/treatment in osteoarthritis.Curator reviewed
Formula / weight: C₂₄H₂₇N₃O₇S · 501.55 g/mol (avg)
Code names: PG-116800 · PG-530742 · PGE-7113313

Resolves to

Compound

UNIIF94T42GL80CAS291533-11-4ChEMBLCHEMBL4297318

Structure

InChIKeyJAYVKNDQKXUNOJ-UHFFFAOYSA-NSMILESCOC1=CC=C(C=C1)C(=O)NC1=CC=C(C=C1)S(=O)(=O)NC(CC#CCN1CCOCC1)C(O)=O

Targets

P08254MMP3P14780MMP9

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with PG-530742, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account